What IV antibiotic(s) and dosing are recommended for treating cellulitis, including options for MRSA and renal impairment?

IV Antibiotic Therapy for Cellulitis

For hospitalized adults with complicated cellulitis, vancomycin 15–20 mg/kg IV every 8–12 hours is the first-line agent, with cefazolin 1–2 g IV every 8 hours preferred when MRSA risk factors are absent. 1

When IV Therapy Is Indicated

Hospitalize and initiate IV antibiotics when any of the following are present:

• Systemic inflammatory response syndrome (fever >38°C, tachycardia >90 bpm, tachypnea >24 breaths/min) 1
• Hypotension, altered mental status, or hemodynamic instability 1
• Severe immunocompromise or neutropenia 1
• Signs of necrotizing infection (severe pain out of proportion, skin anesthesia, rapid progression, "wooden-hard" tissue, gas or bullae) 1
• Failure of outpatient oral therapy after 24–48 hours 1

Important caveat: Oral antibiotics are as effective as IV therapy for uncomplicated cellulitis of similar severity, with no difference in clinical outcomes at days 10 and 30. 2, 3 The decision to use IV therapy should be based on severity markers, not reflexive hospitalization.

First-Line IV Regimens by Clinical Scenario

Uncomplicated Cellulitis Requiring Hospitalization (No MRSA Risk Factors)

Cefazolin 1–2 g IV every 8 hours is the preferred beta-lactam, achieving 96% clinical success in typical cellulitis. 1 Alternative: nafcillin 2 g IV every 6 hours or oxacillin 2 g IV every 6 hours. 1

MRSA coverage is NOT routinely needed even in hospitals with high MRSA prevalence, as MRSA is an uncommon cause of typical non-purulent cellulitis. 1

Complicated Cellulitis with MRSA Risk Factors

Add MRSA-active therapy only when specific risk factors are present:

• Penetrating trauma or injection drug use 1
• Purulent drainage or exudate 1
• Known MRSA colonization or prior MRSA infection 1
• Failure of beta-lactam therapy after 48–72 hours 1

Vancomycin 15–20 mg/kg IV every 8–12 hours (target trough 15–20 mg/L) is first-line for MRSA coverage (A-I evidence). 1

Equally effective alternatives (all A-I evidence):

• Linezolid 600 mg IV twice daily 1
• Daptomycin 4 mg/kg IV once daily 1
• Telavancin 10 mg/kg IV once daily 1
• Clindamycin 600 mg IV every 8 hours (only if local MRSA clindamycin resistance <10%; A-III evidence) 1

Severe Cellulitis with Systemic Toxicity or Suspected Necrotizing Fasciitis

Mandatory broad-spectrum combination therapy is required immediately:

Vancomycin 15–20 mg/kg IV every 8–12 hours PLUS piperacillin-tazobactam 3.375–4.5 g IV every 6 hours 1

Alternative combinations:

• Vancomycin + meropenem 1 g IV every 8 hours 1
• Vancomycin + ceftriaxone 2 g IV daily + metronidazole 500 mg IV every 8 hours 1
• Linezolid 600 mg IV twice daily + piperacillin-tazobactam 1

Obtain emergent surgical consultation when necrotizing infection is suspected—antibiotics alone are insufficient without debridement. 1

Renal Dose Adjustments

Vancomycin in Renal Impairment

For CrCl 30–70 mL/min: Give loading dose of 25–30 mg/kg to rapidly achieve therapeutic levels, then adjust maintenance dosing based on renal function with therapeutic drug monitoring targeting trough 15–20 mg/L. 4

Specific dosing recommendations:

• CrCl 80–100 mL/min: 20 mg/kg every 12 hours 4
• CrCl 70 mL/min: 18 mg/kg every 12 hours 4
• CrCl 50–60 mL/min: 25 mg/kg every 24 hours 4
• CrCl 40 mL/min: 22 mg/kg every 36 hours 4
• CrCl 30 mL/min: 18 mg/kg every 48 hours 4

Loading doses are essential in critically ill patients to rapidly achieve therapeutic drug levels due to expanded extracellular volume from fluid resuscitation. 1

Cefazolin in Renal Impairment

For GFR 59 mL/min (mild renal impairment): Standard dose of cefazolin 1–2 g IV every 8 hours requires no adjustment. 1 Most oral antibiotics for cellulitis also require no dose adjustment at this level of renal function. 1

Treatment Duration

For uncomplicated cellulitis: 5 days if clinical improvement occurs (resolution of warmth/tenderness, improving erythema, afebrile); extend only if symptoms persist. 1 High-quality RCT evidence shows 5-day courses are as effective as 10-day courses. 1, 2

For complicated infections requiring hospitalization: 7–14 days, individualized based on clinical response. 1

For severe cellulitis with systemic toxicity: 7–10 days minimum, reassessing at 5 days. 1

Transition to Oral Therapy

Switch to oral antibiotics once clinical improvement is demonstrated, typically after a minimum of 4 days of IV treatment. 1

Oral options for continued MRSA coverage:

• Clindamycin 300–450 mg every 6 hours (if local resistance <10%) 1
• Linezolid 600 mg twice daily 1
• TMP-SMX 1–2 double-strength tablets twice daily + a beta-lactam 1

For non-MRSA cellulitis: Transition to cephalexin 500 mg every 6 hours, dicloxacillin 250–500 mg every 6 hours, or amoxicillin. 1

Pediatric IV Dosing

Vancomycin 15 mg/kg IV every 6 hours is first-line for hospitalized children with complicated cellulitis (A-II evidence). 1

Alternatives:

• Clindamycin 10–13 mg/kg/dose IV every 6–8 hours (if local resistance <10%; A-II evidence) 1
• Linezolid: 600 mg IV twice daily for children >12 years, or 10 mg/kg/dose IV every 8 hours for children <12 years 1

Critical Pitfalls to Avoid

Do not use vancomycin alone for open-wound cellulitis—it lacks activity against gram-negative and anaerobic pathogens that commonly colonize such wounds. 1

Do not add MRSA coverage reflexively for typical non-purulent cellulitis without the specified risk factors; this overtreats ~96% of cases and promotes resistance. 1

Do not delay surgical consultation when signs of necrotizing infection are present—these infections progress rapidly and require debridement, not just antibiotics. 1

Do not continue ineffective antibiotics beyond 48 hours—progression despite appropriate therapy indicates resistant organisms or deeper infection. 1

Nephrotoxicity limits glycopeptide use—monitor renal function closely with vancomycin and teicoplanin. 5 Consider linezolid or daptomycin as alternatives when nephrotoxicity is a concern. 5

Adjunctive Measures

Elevate the affected extremity above heart level for at least 30 minutes three times daily to promote gravity drainage of edema and hasten improvement. 1

Treat predisposing conditions including venous insufficiency, lymphedema, chronic edema, tinea pedis, and toe web abnormalities to reduce recurrence risk. 1

Systemic corticosteroids (prednisone 40 mg daily for 7 days) could be considered in non-diabetic adults, though evidence is limited (weak recommendation, moderate evidence). 1, 6 NSAIDs as adjunct therapy may lead to improved early clinical response at day 3, although this benefit is not sustained beyond 4 days. 6